Task Force 4: Clinical Considerations for the Care of Athletes with Genetic Cardiomyopathies

The updated AHA/ACC Scientific Statement on Clinical Considerations for Competitive Sports Participation for Athletes with Cardiovascular Conditions presents the clinical considerations for athletes with genetic cardiomyopathies, including hypertrophic, dilated, arrhythmogenic, and left ventricular hypertrabeculation. This ACSM Official Pronouncement complements the 2020 ACC/AHA Scientific Statement by providing athlete-specific context, practical guidance for shared decision-making, and genotype-informed risk assessment for competitive sports participation, moving away from blanket sports disqualifications. Sports participation recommendations for each condition are tailored to risk levels, symptomatology, and genotype. Regular follow-ups and close surveillance are advised. This evolving approach underscores the importance of individualized care, ongoing research, and the integration of new data to better inform shared decision-making on the risks and benefits of competitive sports in athletes with cardiomyopathies.

Authors

Institutions

Publication Details

Journal
Medicine & Science in Sports & Exercise
Published
2026-11-13
DOI
https://doi.org/10.1249/mss.0000000000004092
Primary Topic
Cardiovascular Effects of Exercise
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Task Force 4: Clinical Considerations for the Care of Athletes with Genetic Cardiomyopathies

Sabiha Gati, Jonathan H. Kim, Michael John Ackerman, Aaron Leigh Baggish et al.
5 links
Medicine & Science in Sports & Exercise
Cardiovascular Effects of Exercise
article

Task Force 4: Clinical Considerations for the Care of Athletes with Genetic Cardiomyopathies

Sabiha Gati, Jonathan H. Kim, Michael John Ackerman, Aaron Leigh Baggish, Sharlene M. Day, Benjamin D. Levine, Martin Maron, Matthew Martinez
article en

Abstract

The updated AHA/ACC Scientific Statement on Clinical Considerations for Competitive Sports Participation for Athletes with Cardiovascular Conditions presents the clinical considerations for athletes with genetic cardiomyopathies, including hypertrophic, dilated, arrhythmogenic, and left ventricular hypertrabeculation. This ACSM Official Pronouncement complements the 2020 ACC/AHA Scientific Statement by providing athlete-specific context, practical guidance for shared decision-making, and genotype-informed risk assessment for competitive sports participation, moving away from blanket sports disqualifications. Sports participation recommendations for each condition are tailored to risk levels, symptomatology, and genotype. Regular follow-ups and close surveillance are advised. This evolving approach underscores the importance of individualized care, ongoing research, and the integration of new data to better inform shared decision-making on the risks and benefits of competitive sports in athletes with cardiomyopathies.

Medicine & Science in Sports & ExerciseVol. 58(12)
Lahey Hospital and Medical Center (US), Mayo Clinic (US), Emory University (US), Morristown Medical Center (US), Royal Brompton Hospital (GB), Lahey Medical Center (US), Imperial College London (GB), Atlantic Health System (US), University of Pennsylvania (US), The University of Texas Southwestern Medical Center (US), University of Lausanne (CH)
Good health and well-being
Cardiovascular Effects of Exercise
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon